New PPP Hospital in Tulsa Scheduled to Open in 2024

The Eastern Oklahoma Veterans Affairs Health Care System will expand healthcare for Veterans by opening a new 58-bed VA hospital in Tulsa, US which will be part of the Oklahoma State University Medical Center Campus.

It is the first VA hospital in the nation built as part of a public-private partnership and the first VA hospital built under the Communities Helping Invest through Property and Improvements Needed for Veterans Act of 2016 (CHIP-IN Act). The act authorizes VA to form a public-private partnership and accept up to five donations from non-federal entities.

The project is a combination of federal and private funds from the Anne & Henry Zarrow Foundation. The State of Oklahoma is also assisting by donating the Kerr-Edmondson buildings, which will be converted into the hospital. The City of Tulsa has committed to building a parking garage on site.

The new hospital is part of VA’s efforts to expand services in the Tulsa metro area and northeast Oklahoma. While Eastern Oklahoma VA serves Veterans in 25 counties in eastern Oklahoma, approximately 72% of Veterans live in the Tulsa metro area.

“The new VA hospital in Tulsa is a historic victory. It will offer long lasting and far-reaching benefits for our Veterans, VA and our community,” said Mark E. Morgan, director of the Eastern Oklahoma VA Health Care Center.

Source and image: VAntrage Point, an official website of the U.S. Department of Veterans Affairs.

#PPPsAgainstCorona: Workshop on Public-Private Partnership Responses to COVID-19 and Future Pandemics, the National Academies of Sciences, Engineering, and Medicine (USA) (25-26 June , 2020)

Pandemics, like COVID-19, present unique global health challenges that, by necessity, are catalyzing make-shift and long-term PPPs to remediate unprecedented burdens on the healthcare infrastructure and on morbidity and mortality.

As COVID-19 is now infecting people in countries across the world, the field of global public health is prompted to analyze what PPP-generated global health practices have worked in the past to respond to epidemics and pandemics, and whether or not those response frameworks inform current and future pandemic responses.

The problems pandemics create may be universal (e.g., in terms of pathways to transmission) but also context-specific, as different countries have different capacities to address these challenges, as well as different priorities. As PPPs are now being forged upon the need to respond to COVID-19, there is also an opportunity to define what recent PPP and private sector innovations may serve to inform future handlings of pandemics affecting low-and middle-income countries (LMICs) and high income countries (HICs), as well as what innovations might currently exist in certain global regions that could be transferred to new interventions that may combat COVID-19. Such an analysis may promote information-sharing in live time to combat COVID-19, as well as inform best practices for future outbreaks.

As the world draws closer through the COVID-19 crisis, and those in HICs now face equipment, space, and staffing shortages often seen in LMICs, there is a need to analyze PPP pandemic responses through the larger framework of how they may serve the needs of the global public good, to extend needed support to all countries and people. In a similar vein, the COVID-19 crisis has revealed that PPP responses to pandemics also need to define, adapt, and mechanize a broader global health security agenda that builds global and country-level capacity to address future pandemics.

To explore these topics, this workshop has invited some of the world’s top experts in pandemic response, who will:

(1) review best practices and critical actions from past PPP epidemic and pandemic responses to determine if past response frameworks have applications for the current COVID-19 pandemic;

(2) explore PPP innovations and models that are addressing COVID-19 in country settings;

(3) examine PPP pandemic responses that increase and help navigate the distribution of global public goods; and

(4) discuss PPP pandemic responses that enable the development of a broader global health security agenda.

Read more

Bringing together public and private sectors to lead a mental health and suicide prevention response during COVID-19

Photo by Priscilla Du Preez

Through the Mental Health & Suicide Prevention National Response to COVID-19 (National Response), diverse partners are bringing their best in science, innovation, and leadership to create sustainable and comprehensive solutions to the mental health impacts of this pandemic.

As a national convener, the National Action Alliance for Suicide Prevention (Action Alliance)—the US nation’s public-private partnership—is mobilizing diverse sectors to collectively lead a coordinated mental health and suicide prevention response effort during and in the aftermath of COVID-19.

Read more

The US to launch public-private partnership to speed COVID-19 vaccine and treatment options

adam-niescioruk

The National Institutes of Health and the Foundation for the NIH (FNIH) are bringing together more than a dozen leading biopharmaceutical companies, the Health and Human Services Office of the Assistant Secretary for Preparedness and Response, the Centers for Disease Control and Prevention, the U.S. Food and Drug Administration and the European Medicines Agency to develop an international strategy for a coordinated research response to the COVID-19 pandemic. The planned Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) partnership will develop a collaborative framework for prioritizing vaccine and drug candidates, streamlining clinical trials, coordinating regulatory processes and/or leveraging assets among all partners to rapidly respond to the COVID-19 and future pandemics.

Coordinated by the FNIH, ACTIV government and industry partners will provide infrastructure, subject matter expertise and/or funding (both new and in-kind) to identify, prioritize and facilitate the entry of some of the most promising candidates into clinical trials. Industry partners also will make available certain prioritized compounds, some of which have already cleared various phases of development, and associated data to support research related to COVID-19.

ACTIV will have four fast-track focus areas:

  1. Standardize and share preclinical evaluation methods in an open forum that allows for comparison and validation by:
  2. Prioritize and accelerate clinical evaluation of therapeutic candidates with near-term potential by:
  3. Maximize clinical trial capacity and effectiveness by:
  4. Advance vaccine development

“This powerful public-private partnership will focus and expedite R&D activities required to combat COVID-19,” says Maria C. Freire, Ph.D., President and Executive Director, FNIH. “Working in lock-step, the public and private sectors will maximize the chances of success and provide a roadmap to pre-emptively manage future threats.”

More information